C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease

Clinical Laboratory

Volumn 53, Issue 1-2, 2007, Pages 49-56

  Kazemi Bajestani, Seyyed Mohammad Reza ^a   Ghayour Mobarhan, Majid ^a,b   Ebrahimi, Mahmoud ^a,b   Moohebati, Mohsen ^a,b   Esmaeili, Habib Allah ^a,b   Ferns, Gordon A A ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; IRAN; LIPID BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ANGIOPLASTY; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; IRAN; LIPIDS; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 33847680879     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Pepys M.B. C-reactive protein fifty years on. Lancet 1981; 1: 653-57
2. Pasceri V, Willerson JT, Yeh ET. Direct pro-inflammatory effect of C-rcactives protein on human endothelial cells. Circulation 2000; 102:2165-8
3. Zwaka T.P, Hombach V, Torzewski J. C-reactive protein-mediared low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation 2001; 103:1194-7
4. Berk B.C, Weintraub W.S, Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65:168-72.
5. Ford E.S, Giles W.H. Serum C-reactive protein and fibrinogen concentrations and self reported angina pectoris and myocardial infarction: findings from National Health and Nutrition Examination Survey III. J Clin Epidemiol 2000; 53: 95-102.
6. De Beer F.C, Hind C.R. K, Fox K. M, Allan R.M, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in acute myocardial infarction. Br Heart J 1982; 42: 239-43.
7. Berk BC, Weintraub W.S, Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990; 65: 168-72.
8. Liuzzo G, Biasucci L.M, Gallimore J.R et al. Prognostic value of C-reactive protein and plasma amyloid protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
9. Thompson S.G, Kienast J, Pyke S.D.M, Haverkate F, van de Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
10. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
11. Kuller L.H, Tracy R.P, Shaten J, Mcilahn E.N. for the MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control Study. Am J Epidemiol 1996; 144: 537-47.
12. Hung M.J, Cherng W.J, Yang N.I, Cheng C.W, Li L.F. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. Am J Cardiol 2005, 96 1484-90.
13. Hong YJ, Jeong M.H, Lim S.Y et al. Elevated pre-procedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis developinent after successful coronary artery stenting. Circ J 2005: 69: 1477-83.
14. Mendall M.A, Patel P, Ballam L, Strachan D, Northifield T.C. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996: 312: 1061-65.
15. Marroquin O, Kip K, Kelley DE, Johnson D, Shaw L, C. Merz N, Sharaf B, Pepine C, Sopko G, Reis S. Metabolic syndrome modifies the cardiovascular risk associated with antiiographic coronary artery disease in women: A report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109: 714-21.
16. Gabir MM, Hanson RE, Dabelea D, Imperatore G, Romnain J, Bennett PH, Knowler WC. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23:1108-12.
17. The Seventh Report of the Joint National Committee on: Prevention, Detection, Evaluation and Treatment of High Blood Pressure. U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. December 2003.
18. Lagrand W.K, Visser C.A, Hermens W.T et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999; 100:96-102.
19. Cermak J, Key N.S, Bach R.R ct al. C-reactive protein induces peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513-20.
20. van der Wal A.C, Becker A.E. Atherosclerotic plaque rupture - pathologic basis of plaque stability and instability. Cardiovasc Res 1999; 41:334-44
21. Yeh E.T, Anderson H.V, Pasceri V et al. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001: 104:974-5.
22. Pasceri V, Willerson JT, Yeh ET. Direct pro-inflammatory effect of C-reactives protein on human endothelial cells. Circulation 2000:102:2165-8
23. Zwaka T.P, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation 2001 ; 103:1194-7
24. Verma S, Li S.H, Badiwala M.V et al. Enclothelin antagonism and interleLikin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105:1890-6
25. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur H J 2004; 25: 401-08.
26. Yoshimoto T, Nakanishi K, Hirose S at al. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL1/tumor necrosis factor. J Immunol 1992; 148: 3596-603.
27. Serneri G.G, Abbate R, Gori AM et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992; 86: 790-7.
28. Mazzone A, De Servi S, Ricevuti G et al. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993; 88: 358-63.
29. Colhoun H.M, Schalkwijk C, Rubens M.B, Stchouwer C.D. C-reactive protein in type 1 diabetes and its relation to coronary artery calcification. Diabetes Care 2002; 25: 1813-17.
30. Scholin A, Seigbalm A, Lind L et al. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell fuction during the first year after diagnosis of type 1 diabetes. Diabetes Metab Res Rev 2004; 20: 205-10.
31. Folsom A.R, Golden S.H, Boland L.L, Szklo M. Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women. Eur J Epidemiol. 2005; 20: 1015-22.
32. Rossouw J.E, Anderson J.L, Prentice R.L et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
33. Pradahan A.D, Manson J.E, Rossouw J.E et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative Observational Study. JAMA 2002; 288: 980-7.
34. Saito M, Ishimitsu T, Minami J et al. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167: 73-79.
35. Bermudez E.A, Rifai N, Buring J.E, Manson J.E, Ridker PM. Relation between markets of systemic vascular inflammation and smoking in women. Am J Cardiol 2002; 89:1117-19.
36. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138:891-7.
37. Targher G, Zenari L, Faccini G, Falezza G, Muggeo M, Zoppini G. Serum leptin concentrations in young smokers with type 1 diabetes. Diabetes Care 2001; 24:793.
38. Kim S.H, Kim J.S, Shin H.S, Keen C.L. Influence of smoking on markets of oxidative stress and serum mincral concentrations in teenage girls in Korea. Nutrition 2003; 19: 240-43.
39. Xu H, Barnes G.T, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
40. Gillum R.F. Association of serum C-reactive protein and indices of body fat distribution and overweight in Mexican American children. J Natl Med Assoc 2003; 95: 545-552.
41. Forouhi N.G, Sattar N, Mc-Kcigue P.M. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001; 25: 1327-1331.
42. Bullo M. Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11:525-53 .
43. Lemieux I, Pascot A, Prud'homme D et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vase Bioi 2001; 21: 961-967.
44. Jankowska E.A, Rogucka E, Medras M, Welon Z. Relationships between age-related changes of sex steroids, obesity and body fat distribution among healthy Polish males. Med Sci Monit 2000; 6: 1159-64.
45. Molian V, Deepa K, Velmurugan, Premalatha G. Association of C-reactive protein with body fat, diabetes and coronary artery disease in Asian Indians: The Chennai Urban Rural Epidemiology Study (CURES-6). Diabetes Med 2005; 22:863-70.
46. Tainakoshi K, Yatsuya H, Kondo T et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003; 27: 443-49.
47. Yan R.T. Yan A.T, Tan M et al. Age-related differences in the management and outcome of patients with acute coronary syndromes. Am Heart J 2006; 15 1:352-359.
48. Marin A, Medrano M.J, Gonzalez J et al. Risk of ischernic heart disease and acute myocardial intaretion in a Spanish population: observational prospective study in a primary-care setting. BMC Pub Health 2006; 17: 6-38.
49. Mc-Clelland R.L, Chung H, Detrano R, Post W, Kronmal R.A. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2006; 113: 30-37.
50. da Luz PL, Ccsena F.H, Favarato D, Cerqucira E.S Comparison of serum lipid values in patients with coronary artery disease at <50, 50 to 59, 60 to 69, and >70 years of age. Am J Cardiol 2005; 96:1640-43.
51. Ferrara N, Corbi G, Bosimini E et al. Cardiac rehabilitation in the elderly: patient selection and outcomes. Am J Geriat Cardiol 2006; 15:22-27.
52. Hokanson J.E, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-dcnsity lipoprotein cholesterol level: a ineta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3:213-19.
53. Holvoet P, Macy E, Landeloos M et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem 2006; 52:760-4.
54. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15:2073-84.
55. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995, 57:791-804.
56. Koba S, Hirano T, Ito Y et al. Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis (article in press).
57. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002; 105:2696-98.